A-B. Loembé

Suggest Changes
  • Citations Per Year
Learn More
This multicentre, open-label, phase-I/randomised phase-II trial evaluated safety, pharmacokinetics, maximum-tolerated-dose (MTD) per dose-limiting toxicities (DLTs), and efficacy of nintedanib vs.(More)
  • 1